Tortugas Neuroscience, a neurology-focused biotech company developing novel medicines with derisked mechanisms of actions, for large and well-defined indications, has announced a $106 million Seed and Series A financing round. The funding will support ongoing research and development initiatives, including the completion of Phase 2 clinical trials for its two lead candidates.

Founding investor Cure Ventures, a life sciences venture capital firm focusing on de novo company formation around groundbreaking technologies, led the Seed round, and will co-lead the Series A round along with The Column Group and AN Venture Partners.

Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. With a strategic focus on derisked mechanisms and rapid development pathways, Tortugas Neuroscience is committed to creating therapies with meaningful impact for patients worldwide.